Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Paxlovid
Nirmatrelvir is an antiviral medication specifically developed for the treatment of COVID-19. It is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), also known as 3CLpro, a key enzyme essential for viral replication. It is typically co-administered with ritonavir, which slows the metabolism of nirmatrelvir, boosting its concentration in the body and enhancing its effectiveness. Nirmatrelvir/ritonavir is generally prescribed for mild-to-moderate COVID-19 in adults and certain pediatric patients who are at high risk of progressing to severe illness.
Nirmatrelvir is used in combination with ritonavir to treat mild-to-moderate COVID-19 in adults and certain pediatric patients at high risk of progression to severe disease.
Outcome:
Increased nirmatrelvir levels
Mechanism:
CYP3A4 inhibition
Outcome:
Increased sildenafil levels
Mechanism:
CYP3A4 inhibition
Outcome:
Minor increase in fexofenadine levels
Mechanism:
P-gp inhibition
Most likely new formulation: Extended-release formulation or combination with other antivirals (2025, 75% confidence)
Based on current usage and clinical trial data, there is a high likelihood (>90%) that nirmatrelvir will remain a key therapeutic option for COVID-19 treatment in the near future.
Antiviral
Peptidomimetic